Clinical EvaluatioN of TElmisartan-based Antihypertensive Regimen

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension; Metabolic Syndrome X

Study type: Observational

Funder types: Industry

Identifiers

NCT00613314

502.532

Details and patient eligibility

About

To determine the efficacy and safety of telmisartan-based treatment among patients with metabolic syndrome in actual setting in Philippines.

Enrollment: 15,268 patients

Sex: All

Ages: 45+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 45 years
• Increased waist circumference (>88.9cm [>35in] men, >78.7cm [>31in] for women)
• Elevated triglycerides (>150mg/dl)
• Low HDL cholesterol (<40mg/dl in men, <50mg/dl in women)
• Hypertension (>130/>85mmHG)
• Impaired fasting glucose (>110mg/dl) (8)
• Hypertensive patient assessed to benefit from telmisartan based treatment

Exclusion criteria

• Hypersensitivity to telmisartan, hydrochlorothiazide (HCTZ) and its excipients
• <3 months myocardial infarction (MI), stroke or severe heart failure